Glutathione S-transferase M1 and T1, CYP1A2-2467T/delT polymorphisms and non small-cell lung cancer risk in Tunisian sample by Fatma, B et al.
The Egyptian Journal of Medical Human Genetics (2012) 13, 307–312Ain Shams University
The Egyptian Journal of Medical Human Genetics
www.ejmhg.eg.net
www.sciencedirect.comORIGINAL ARTICLEGlutathione S-transferase M1 and T1,
CYP1A2-2467T/delT polymorphisms and non
small-cell lung cancer risk in Tunisian sampleB’chir Fatma
a,b,*, Taieb Aida
b




a Laboratory of Natural Substances, National Institute of Research and Physical–Chemical Analysis (INRAP), Technopole Sidi
Thabet 2020, Tunisia
b Metabolic Biophysics and Applied Pharmacology Laboratory, Department of Biophysics, Medicine Faculty of Sousse, 4002
Sousse, Tunisia
c Nutrition and Biochemistry, 1814 La Tour de Peilz, SwitzerlandReceived 20 February 2012; accepted 7 May 2012












Lung cancerCorresponding author at:
ational Institute of Resear
NRAP), Technopole Sidi Th
7; fax: +216 73 224 899.
mail address: bchirfatma@h
er review under responsibilit
Production an








g.2012.0Abstract The present study investigated the impact of metabolic gene polymorphisms in modulat-
ing lung cancer risk susceptibility. Gene polymorphisms encoding Cytochrome 1A2 (CYP1A2) and
Glutathione-S-transferases (GSTT1 and GSTM1) are involved in the bioactivation and detoxifica-
tion of tobacco carcinogens and may therefore affect lung cancer risk.
In order to assess association between lung cancer and GSTT1, GSTM1 and CYP1A2-2467T/
delT, variant allele (CYP1A2*1D) polymorphisms, a case–control study of healthy and smoking
lung cancer patients in Tunisian population was conducted. Polymorphisms of GSTs were assayed
by multiplex PCR. Genotype polymorphism of CYP1A2*1D was determined by PCR-RFLP assay.
Odds Ratio was used for analysing results.
There was no association with any increase of lung cancer risk in GSTT1 null genotype [OR: 0.83
(0.47–1.45)] as well as in GSTM1 null genotype [OR: 0.78 (0.37–1.62)]. However, a significant asso-
ciation between lung cancer and the homozygous mutate variant of the CYP1A2 [(OR = 4.7 (1.55–
29.78)] was observed.ory of Natural Substances,
Physical–Chemical Analysis
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308 B. Fatma et al.These results demonstrated that the strong and significant association between CYP1A2*1D and
lung cancer appears to be relevant in this Tunisian population, suggesting that CYP1A2 metabolic
genetic factor may, in partly, play a role in modulating lung cancer susceptibility.
 2012 Ain Shams University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Lung cancer is the most common cause of death in several
developing countries. Its increasing incidence and mortality
are observed all over the world [1]. Tobacco smoking is the
main and predominant risk factor for lung cancer disease.
Worldwide, the lung cancer mortality in the population due
to smoking is estimated to 79% for men and 48% for women
[2,3]. However an increased incidence of lung cancer has also
been observed in non-smokers [3,4] and in addition to tobacco
smoke, lung cancer is known to be associated with other risk
factors such as diet, air pollution and occupational exposures
to carcinogens [3].
Although smoking remains the most known risk factor for
lung cancer development it might be hypothesised that early-
onset of lung cancer among both smokers and non-smokers
may have a stronger genetic component in its pathology
[5,6]. This genetic component may modulate the risk associ-
ated with environmental factors.
Polymorphisms in genes encoding for xenobiotic metabo-
lism of phase I and phase II enzymes such as the cytochrome
P450 1A2 (CYP1A2) a phase I enzyme and the glutathione-
S-transferase theta 1 gene (GSTT1) and the glutathione-S-
transferase mu 1 gene (GSTM1) isoenzymes from phase II
detoxifying family are more studied recent years in particular
in the field of their association with diseases.
GSTs catalyse electrophilic metabolites through conjuga-
tion with reduced glutathione followed by excretion from the
body. Both GSTT1 and GSTM1 are particularly attractive
candidates for lung cancer susceptibility because of their
involvement in the detoxification of several carcinogenic com-
pounds found in tobacco smoke and in chemicals and environ-
mental exposure [7].
GSTM1 has been found to detoxify Polycyclic Aromatic
Hydrocarbons (PAH) present in tobacco smoke. GSTT1 is in-
volved in the metabolism of smaller compounds also found in
tobacco smoke, such as monohalomethane and ethylene oxide
[8]. So deletions in GSTs genes are considered as potential
modifiers of individual lung cancer risk.
CYP1A2 is a phase I enzyme, involved in the activation of
several indirect carcinogens such as nitrosamines, Aromatic
Heterocyclic Amine (AH)) which are present in the main
stream of tobacco smoke [9]. As a consequence, the formation
of reactive metabolites and their binding to DNA gave then
stable adducts which are considered as the critical step in the
initiation of carcinogenic process. Thus, high activity of
CYP1A2 was therefore suggested as a potential risk factor
for lung cancer.
Several environmental factors as well as tobacco smoke
have been shown to induce CYP1A2 activity. As the study
of Pavanello [10,11], it was shown that genetic polymorphism
in non coding CYP1A2 promoter, the CYP1A2*1D variant al-
lele which consists of the deletion of T base (2467T/delT) in-
creases the CYP1A2 activity in smokers. This informationsuggests that this mutation may interfere and affect the suscep-
tibility to lung cancer.
In this context, this study has been undertaken to address
the association of both metabolic genes CYP1A2*1D phase I
enzyme and GSTT1-M1 phase II enzymes with lung cancer
susceptibility among Tunisian smokers.
2. Subjects and methods
Ninety-eight healthy subjects and 101 lung cancer cases,
including 41 patients with Adenocarcinoma (AD) and 60 pa-
tients with Squamous Cell Carcinoma (SCC) histological cell
types participated to this study.
Lung cancer cases were enrolled from ‘‘CHU Farhat Ha-
ched of Sousse’’ central hospital of Tunisia from June 2004
to July 2005. They are all men and current smokers. Classifica-
tions and histological types of lung cancer cases were assessed
by fibre optic bronchoscopy technique.
At recruitment, each participant was interviewed to obtain
detailed information on their tobacco use and possible expo-
sure to carcinogens through dietary habits and professional
activities. All information regarding participants was made
anonymous after collection of data and blood samples. In-
formed consent was obtained from each participant before
interview and blood collection for genetic analysis.
The study was approved by the Ethics Committee of the
Hospital in Sousse [12].
Variables selected from the data are: age, histology of cell
cancer, smoking status, packs-years of smoking, types of ciga-
rette smoked and the mean daily cigarettes smoked.
Other variables, such occupational exposure, family history
of cancer, were available but not considered in this analysis.
The Controls selected were all men and current smokers.
The controls were matched for gender, age and smoking status
with the cases.
A 5 ml sample of whole blood was collected from each sub-
ject in a 7 ml K3ETDA tube for genetic analysis.
The presence of GSTT1 and GSTM1 genes was determined
using multiplex Polymerase Chain Reaction (PCR)
methodology.
Allelic variants 2467 T/delT (allele* 1D) of CYP1A2 gene
were performed by PCR-restriction fragment length polymor-
phism analysis [11].
3. Statistical analysis
Data were analysed using SPSS 0.11 statistical software. Odds
Ratio (OR) was calculated by logistic regression in exact 95%
confidence interval (CI).
4. Results
Relevant characteristics of patients and controls are given in
Table 1. Cases were ever smokers more than controls. The
Table 1 Characteristics of lung cancer cases and controls [11].
Characteristics Cases Controls
All n= 101 (%) SCC n= 60 (%) AD n= 41 (%) n= 98%
Gender
Male 101 (100) 60 (100) 41 (100) 98 (100)
Female 0 (0) 0 (0) 0 (0) 0 (0)
Age (years)
Median 56 56 56 56
Range 37–84 38–82 37–84 36–84
Smoking by pack-years
Median 45 45 40 38
Range 13–120 23–114 23–120 15–114
Years smoked
Median 30 30 30 30
Range 15–59 17–59 15–50 10–64
Mean daily cigarettes
Median 30 30 30 20
Range 10–65 10–60 20–65 10–50
Table 2 Association between GSTT1, GSTM1 and CYP1A2 gene polymorphisms and lung cancer risk.
Gene Cases Controls OR (95% CI) P value
N (%) N (%)
GSTT1
Present 82 (81.18) 82 (83.67) 1.0
Absent 19 (19.4) 16 (15.8) 0.83 (0.47–1.45) 0.51
GSTM1
Present 51 (50.5) 53 (54%) 1.0
Absent 50 (49.5) 45 (45.9) 0.78 (0.37–1.62) 0.51
CYP1A2*1D
Wild type 80 (79.2) 88 (89.8) 1.0
Heterozygous 19 (18.8) 7 (7.1) 1.36 (0.22–8.37) 0.73
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trols (P < 0.05).
Table 2 gives the analysis and the distribution of GSTT1,
GSTM1 and 2467delT CYP1A2*1D genotypes among cases
and controls. GSTM1 null genotype was more frequent than
GSTT1 null genotype. They were present respectively in
15.8% and in 45.9% among healthy controls.
The prevalence of GSTT1 null genotype in lung cancer pa-
tients was 19.4% compared to 15.8% in controls. Frequencies
of GSTM1 gene deletion were 49.5% in patients and 45.9% in
healthy subjects. The two samples did not differ significantly in
frequencies of null genotypes between patients and controls.
Both GSTT1 and GSTM1 gene deletions were not associ-
ated with any lung cancer risk. Their odds Ratios (ORs) are
0.83 (0.47–1.45 (CI)) for GSTT1 and 0.78 (0.37–1.62(CI)) for
GSTM1.For CYP1A2*1D (2467deltT) distribution, the heterozy-
gous and homozygous mutated variants frequency was present
in11% of controls and 24%of lung cancer cases.
There is a significant association between lung cancer and
the homozygous mutated variant of the CYP1A2 [OR = 4.7
(1.55–29.78)]. Subjects with mutated homozygous CYP1A2
delt/delt genotype present an increased risk of lung cancer of
fourfold higher than subjects with wild type genotype.
Considering the cell type lung cancer, the genotype
2467delt/delt frequency was 7% in AD lung cancer patients
and totally absent in SCC.
For GSTT1 null genotype, it was more frequent in SCC than
AD (21.6% versus 4.87%), while the GSTM1 null genotype dis-
tribution was almost the same in AD and in SCC (Table 3). A
significant association between GSTT1 null genotype and AD
lung cancer risk was registered [OR = 2.35(1.13–5.66)].
Table 3 Frequencies and ORs for the risk of AD and SCC lung cancer associated with GSTT1, GSTM1 and CYP1A2*1D genotypes.
GSTT1 null genotype GSTM1 null genotype CYP1A2*1D
N (%) OR N (%) OR Wild type (%) Heterozygous (%) Mutant (%)
SCC 4.87 0.87 (0.56–8.9) 46.34 0.56 (0.32–41.3) 76 17 0
AD 21.6 2.35(1.13–5.66) 48.33 0.96 (0.98–56.9) 82 18 7
N (%): frequency.
OR: Odds Ratio.
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In this study we have examined the impact of the GSTT1,
GSTM1 and CYP1A2 genes polymorphism on lung cancer
susceptibility among Tunisian population.
GSTT1, GSTM1 and CYP1A2 were the most extensively
investigated polymorphic gene enzymes for lung cancer risk
because of their potential involvement in carcinogenesis pro-
cess [8,13–15]. So the polymorphism in the metabolic activities
of these enzymes may be an important determinant factor for
lung cancer risk.
The most common polymorphism in GSTT1 and GSTM1
consists of a deletion of the whole T1 and M1 genes, resulting
in the lack of active enzymes. The lack of these phase II en-
zymes leads to the decrease of detoxification pathway and
accumulation of carcinogenic metabolites.
The CYP1A2 enzyme is highly expressed in liver and also
expressed at lower frequencies in different parts of lungs in hu-
mans [16–18]. The CYP1A2 plays an important role in the bio-
activation of precarcinogenic environmental toxins [19–21] and
it may be implicated in the initiation and the development of
lung cancer.
Therefore the level of expressions and catalytic activities of
CYP1A2, GSTT1 and GSTM1 enzymes and their metabolic
balance, may be an important determining factor underlying
lung cancer susceptibility.
Several studies have suggested that GSTs genotypes may
play mainly role in determining susceptibility to lung cancer
because of their faculty to eliminate carcinogenic electrophilic
compounds. They have reported that individuals polymorphic
in carcinogen-detoxifying genes may have a weaken ability to
eliminate carcinogenic metabolites and therefore to be at en-
hanced risk of lung cancer [22–25].
However data are often in conflict because of the variations
in the GSTT1 and GSTM1 null allele frequencies in different
ethnic groups [26,27].
In fact, inter-ethnic variations in GSTT1 and GSTM1 null
genotype frequencies are obviously recorded.
50% of Caucasians population present a GSTM1 null
genotype [28], which is in accordance with our Tunisian popu-
lation (45.9%), 33%, of African American and 45% of Japa-
nese have deletion in the GSTM1 gene [29].
Relationship between GSTM1 null genotype and lung can-
cer risk is in conflict according to the results reported from var-
ious researcher groups, some studies showed an increased lung
cancer risk for GSTM1 [22,33] deleted gene and other studies
did not mentioned any association [25,30,31].
In our study, the GSTM1 null genotype was not associated
with any increased risk of lung cancer.
For GSTT1 null genotype, the Tunisian population fre-
quencies were so different to that of frequencies reportedworldwide by Nelson et al. [27]. Our results showed a very
low GSTT1 null genotype frequency (15.8% in healthy sub-
jects) compared to other different ethnic groups. Deletion of
GSTT1 loci was present in 64% of Chinese, 60% of Koreans,
28% of Caucasians and 22% of African American [27].
Despite of the low frequency of GSTT1 gene deletion in the
Tunisian population of this study, an association by histolog-
ical type cells was observed while an absence of association
with global lung cancer risk was recorded. Therefore our re-
sults are not in accordance with those of Sreeja and Sqrensen
[14,32,33] showing that lung cancer patients who were smokers
and having a GSTT1 null genotype had an increased risk
[OR = 2.24, 95%CI (1.020–7.968)] for lung cancer compared
with non-smokers.
However this result suggests that individuals with GSTT1
null genotype, in particular the smokers, are more at risk to de-
velop AD lung cancer and not SCC.
The deletion of GSTT1 loci and the consequent lower
detoxification of xenobiotics, particularly the toxins found in
tobacco smoke and environmental pollution, suggest that indi-
viduals with deleted GSTT1 gene were more susceptible to dis-
ease induced by toxic substances present in environment and
subsequently may contribute to AD lung cancer.
The development of AD cells form occurs in the peripheral
region of the lung, the area where stored the electrophilic
metabolites of main stream smoke [34].
We can suggest that the presence of GSTT1 loci and its
detoxifying functional enzymes may play a defensive role
against the development of AD lung cancer. The genetic poly-
morphism of GST probably plays a role in the pathogenesis of
lung cancer. However, the polymorphisms of these genes may
also interact with dietary intake of isothiocyanates provided by
cruciferous vegetables in the process of lung cancer. Isothiocy-
anates that are metabolised by GST enzymes have been shown
to reduce lung cancer risk and this reduction in risk was stron-
ger among persons with GSTM1 null genotype who metabolise
and eliminate these compounds less rapidly [25].
We observed a higher prevalence of CYP1A2*1D gene
polymorphisms (t/delt, delt/delt) in lung cancer patients when
compared to controls. A strong and significant association was
found between a mutated variant homozygous form CYP1A2
delt/delt and lung cancer risk [OR = 4.07 (1.55–29.78)]. Indi-
viduals with delt/delt allele variant present a fourfold higher
risk to develop lung cancer. This observation, therefore sug-
gests that this mutated genotype may play an important role
in the development of lung cancer. However, the analysis
including both CYP1A2 heterozygous and homozygous vari-
ants show no significant association with histological lung can-
cer cell types risk [OR = 2.08 (0.94–4.71)], although the
CYP1A2 homozygous variant frequency was higher in patient
with AD lung cancer histological type.
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null genotype, CYP1A2 mutated variants and lung cancer cell
types. This observation may be supported by the small size
samples presented in this study which may explain our inability
to identify a significant association of GSTM1 null genotype
and CYP1A21*D with lung cancer cell types susceptibility.6. Conclusion
From the present study, the results showed that only CYP1A2
homozygous mutated genotype was strongly associated with
the risk of lung cancer. This association appears to be poten-
tially relevant in our population in contrast with GST genes.
These results also show that phase II metabolic enzymes do
not seem to be involved in lung cancer risk despite its preven-
tive role.
According to the association between these three gene poly-
morphisms and lung cancer cell types, our study indicates that
only GSTT1 genotype was associated with AD lung cancer
development.
Certain limitations should be mentioned in this study.
Firstly the results should be viewed with caution due to the
small number of subjects genotyped in this study.
Secondly, it would be more efficient to study lung cancer
risks combining the effects of the three polymorphisms CY-
P1A2*1D, GSTT1 and GSTM1, even if the combined action
of phase I and phase II enzymes with increased activation
and decreased detoxification of tobacco smoke carcinogenesis
has been hypothesised to lead to increased lung cancer risk.
Individuals having defective for more than one of these genes
are at greater risk for lung cancer than those having a defective
genotype of only one gene.
Sreeja et al. study has investigated the combination effects
of CYP1A1, GSTT1 and GTTM1 genotypes with lung cancer
susceptibility and has indicated that the CYP1A1 homozygous
variant genotype and GSTT1 null genotype are more strongly
associated with lung cancer risk [14]. It was not possible to ap-
ply this combined effect test in our study due to the small pop-
ulation recruited. However, it would be useful to study the
combining effects of the majority of phase I and phase II met-
abolic genotypes. The presence of CYP1A2 or/and CYP1A1
variant proteins may result in increased formation of carcino-
genic metabolites due to the enhanced phase I enzyme activity,
with the detoxification of the reactive metabolites being re-
duced by the absence of functional phase II enzymes like
GSTT1 and GSTM1, which might have a role in the initiation
of lung cancer.
So it seems useful to propose for further investigations to
study genotypes of the combining effects of both CYP1A2
and CYP1A1 phase I enzymes and GSTTM1 and GSTT1
phase II enzymes in people exposed to environmental toxins.
This way will be more helpful and coherent for the assessment
and to define lung cancer risk.Acknowledgments
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